1) 厚生労働省委託事業血液凝固異常症全国調査. 平成30年度報告.
2) Aletaha D, et al. 2010 Rheumatoid Arthritis Classification Criteria : An American College of Rheumatology/ European League Against Rheumatism Collaborative Initiative. Arthritis Rheum. 2010 ; 62 : 2569-2581.
3) Jansen LM, et al. The Predictive Value of Anti-Cyclic Citrullinated Peptide Antibodies in Early Arthritis. J Rheumatol. 2003 ; 30 : 1691-1695.
4) 三森経世. 抗CCP抗体. 日本内科学会雑誌. 2007 ; 96 : 2132-2137.
5) van Venrooij WJ, et al. Anti-CCP Antibodies : The Past, the Present and the Future. Nat Rev Rheumatol.2011 ; 7 : 391-398.
6) Willemze A, et al. The Influence of ACPA Status and Characteristics on the Course of RA. Nat Rev Rheumatol. 2012 ; 8 : 144-152.
7) Arnold MB, et al. Are There Differences Between Young- And Older-Onset Early Inflammatory Arthritis and Do These Impact Outcomes? An Analysis From the CATCH Cohort. Rheumatology (Oxford). 2014 ; 53 : 1075-1086.
8) Sloane D, et al. Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 ; 4 : 497-504.
9) Mjaavatten MD, et al. Should Anti-Citrullinated Protein Antibody and Rheumatoid Factor Status Be Reassessed During the First Year of Followup in Recent-Onset Arthritis? A Longitudinal Study. J Rheumatol. 2011 ; 38 : 2336-2341.
10) 竹村有美, 他. 半固形化栄養材の人工胃液中での物性変化. 静脈経腸栄養. 2011 ; 26 : 1255-1264.
11) Gupta K, et al. Cranberry Products Inhibit Adherence of P-Fimbriated Escherichia Coli to Primary Cultured Bladder and Vaginal Epithelial Cells. J Urol. 2007 ; 177 : 2357-2360.
12) Takahashi S, et al. A Randomized Clinical Trial to Evaluate the Preventive Effect of Cranberry Juice (UR65) for Patients With Recurrent Urinary Tract Infection. J Infect Chemother. 2013 ; 19 : 112-117.
13) Juthani-Mehta M, et al. Effect of Cranberry Capsules on Bacteriuria Plus Pyuria Among Older Women in Nursing Homes : A Randomized Clinical Trial. JAMA.2016 ; 316 : 1879-1887.
14) 奥田由美, 他. 高齢者の排便コントロールの重要性. 月刊ナーシング. 2012 ; 32 : 117-120.
15) Yamaguchi M, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992 ; 19 : 424-430.
16) Asanuma YF, et al. Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol. 2015 ; 25 : 393-400.
17) Efthimiou P, et al. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis. 2006 ; 65 : 564-572.
18) Shimizu M, et al. Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis. Rheumatology ( Oxford). 2010 ; 49 : 1645-1653.
19) Petri M, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 ; 64 : 2677-2686.
20) Ward CT, et al. Atypical warfarin-induced skin necrosis. Pharmacotherapy. 2006 ; 26 : 1175-1179.
21) Lai J, et al. Anticoagulation therapy for thromboembolism prevention : a case of warfarin-induced skin necrosis in the setting of protein C deficiency. BMJ Case Rep. 2017 ; 2017 : bcr2016218015.
22) Goda K, et al. Adult-onset Still's disease with macrophage activation syndrome diagnosed and treated based on cytokine profiling : a case-based review. Rheumatol Int. 2020 ; 40 : 145-152.
23) Turgut T, et al. Serum interleukin-2 and neopterin levels as useful markers for treatment of active pulmonary tuberculosis. Tohoku J Exp Med. 2006 ; 209 : 321-328.
24) 五十嵐隆, 他. 溶血性尿毒症症候群の診断・治療ガイドライン. 東京医学社 ; 2014.
25) Su C, et al. Escherichia coli O157 : H7 infection in humans. Ann Intern Med. 1995 ; 123 : 698-714.
26) Boyce TG, et al. Escherichia coli O157 : H7 and the hemolytic-uremic syndrome. N Engl J Med. 1995 ; 333 : 364-368.
27) 福田雅通, 他. 溶血性尿毒症症候群典型例16例の腎機能, LDH, 血小板数の推移. 小児科診療. 1996 ; 59 : 1008-1012.
28) Hermos CR, et al. Shiga toxin-producing Escherichia coli in children : diagnosis and clinical manifestations of O157 : H7 and non-O157 : H7 infection. J Clin Microbiol. 2011 ; 49 : 955-959.
29) Tajiri H, et al. A role for fosfomycin treatment in children for prevention of haemolytic - uraemic syndrome accompanying Shiga toxin-producing Escherichia coli infection. Int J Antimicrob Agents. 2015 ; 46 : 586-589.